Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + Huaier granule
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of tislelizumab, a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1), and Huaier granule, a traditional Chinese medicine (TCM) extract derived from the fungus *Trametes robiniophila Murr*. Currently being evaluated by Tongji Hospital as a first-line treatment for unresectable hepatocellular carcinoma (HCC), the regimen utilizes the synergistic potential of immune checkpoint inhibition and the multi-targeted anti-tumor properties of Huaier. Huaier granule contains bioactive components such as polysaccharides and proteins that inhibit tumor cell proliferation, induce apoptosis, and suppress angiogenesis. Furthermore, Huaier has been shown to modulate the tumor microenvironment by promoting CD8+ T cell infiltration and upregulating PD-L1 expression, which may enhance the therapeutic efficacy of PD-1 blockade in HCC patients.
- Brand names
- Tevimbra
- Other names
- Huaier granule and tislelizumab combinationTislelizumab plus Huaier granule
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tislelizumab + Huaier granule.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + Huaier granule.